Compounds of the present disclosure are fused pyrimidine compounds of formula(I), its tautomers, polymorphs,stereoisomers, prodrugs, solvate or a pharmaceutically acceptable saltsthereof, as Adenosine receptor antagonists. Processes oftheir preparation are also described in the disclosure.